Mylan launches generic version of Baxter's Mesnex

PITTSBURGH — Mylan has released a generic version of a drug used to treat a complication of certain chemotherapy regimens, the drug maker said Tuesday.



The company announced the launch of mesna injection in the 100-mg/mL and 1,000-mg/10-mL strengths. The drug is used to reduce the incidence of ifosfamide-induced hemorrhagic cystitis, a possible complication of ifosfamide chemotherapy.



The drug is a generic version of Baxter Healthcare's Mesnex, which has experienced shortages recently. Various versions of the drug had sales of about $11.7 million in 2011, according to IMS Health.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.